Comparative fetomaternal outcomes of acarbose versus insulin in gestational diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Komang Diah Kurnia Kesumaputri; I. Nyoman Windiana; I. Made Mahardika

doi:10.18203/2320-1770.ijrcog20262128

Authors

Komang Diah Kurnia Kesumaputri Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia
I. Nyoman Windiana Faculty of Medicine, Ganesha University of Education, Buleleng, Bali, Indonesia
I. Made Mahardika Department of Obstetrics and Gynecology, Wangaya General Hospital, Denpasar, Bali, Indonesia

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20262128

Keywords:

Acarbose, Fetomaternal, Gestational diabetes mellitus, Insulin

Abstract

The prevalence of gestational diabetes mellitus (GDM) continues to increase globally, particularly in Southeast Asia. Currently, insulin remains the standard therapy for GDM, however its use is invasive and has been associated with hypoglycemia in up to 70% of patients. Acarbose is an alternative oral agent with minimal systemic absorption that works by inhibiting alpha-glucosidase enzyme. Therefore, this study aimed to evaluate the fetomaternal outcomes associated with acarbose therapy in pregnant women with GDM. A systematic search was conducted in PubMed, ScienceDirect, CENTRAL, Google Scholar, and MedRxiv following PRISMA guidelines. Outcomes were analyzed using mean difference (MD) and risk ratio (RR). A total of five studies involving 452 patients were included in the analysis. No statistically significant reduction in HbA1c levels was observed in either group. However, HbA1c tended to be lower in the acarbose group compared with the insulin group (MD=-0.11; 95% CI -0.24, 0.01; p=0.08). Similarly, no significant differences were found in birth weight (MD= -0.11; 95% CI -0.24, 0.01; p=0.08), macrosomia incidence (RR=1.31; 95% CI 0.62, 2.77; p=0.49), or neonatal hypoglycemia (RR=0.56; 95% CI 0.23, 1.36; p=0.20). Nevertheless, neonatal hypoglycemia occurred more frequently in the insulin group than in the acarbose group (20/138 vs 7/91, respectively). Acarbose may be a potential oral alternative for GDM management, demonstrating fetomaternal outcomes comparable to insulin. Nevertheless, future large-scale studies are required to confirm its efficacy and safety.

Metrics

Metrics Loading ...

References

Assani M-Z, Boldeanu L, Manolea M-M, Boldeanu MV, Siloși I, Assani A-D, et al. From molecular insights to clinical management of gestational diabetes mellitus—A narrative review. Int J Mol Sci. 2025;26(17):8719. DOI: https://doi.org/10.3390/ijms26178719

Al Bekai E, Beaini CE, Kalout K, Safieddine O, Semaan S, Sahyoun F, et al. The hidden impact of gestational diabetes: Unveiling offspring complications and long-term effects. Life. 2025;15(3):440. DOI: https://doi.org/10.3390/life15030440

Karami M, Mousavi SH, Rafiee M, Heidari R, Shahrokhi SZ. Biochemical and molecular biomarkers: Unraveling their role in gestational diabetes mellitus. Diabetol Metab Syndr. 2023;15(1):5. DOI: https://doi.org/10.1186/s13098-023-00980-8

Mittal R, Prasad K, Lemos JRN, Arevalo G, Hirani K. Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management. Int J Mol Sci. 2025;26(5):2320. DOI: https://doi.org/10.3390/ijms26052320

Wang H, Li N, Chivese T, Werfalli M, Sun H, Yuen L, et al. IDF Diabetes Atlas: Estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group's Criteria. Diabetes Res Clin Pract. 2022;183:109050. DOI: https://doi.org/10.1016/j.diabres.2021.109050

Li M, Song Y, Rawal S, Hinkle SN, Zhu Y, Tekola-Ayele F, et al. Plasma prolactin and progesterone levels and the risk of gestational diabetes: A prospective and longitudinal study in a multiracial cohort. Front Endocrinol (Lausanne). 2020;11:83. DOI: https://doi.org/10.3389/fendo.2020.00083

American Diabetes Association. Management of diabetes in pregnancy. Diabetes Care. 2017;40:S114-9. DOI: https://doi.org/10.2337/dc17-S016

Rozenkova K, Guemes M, Shah P, Hussain K. The diagnosis and management of hyperinsulinaemic hypoglycaemia. J Clin Res Pediatr Endocrinol. 2015;7(2):86-97. DOI: https://doi.org/10.4274/jcrpe.1891

Guo L, Ma J, Tang J, Hu D, Zhang W, Zhao X. Comparative efficacy and safety of metformin, glyburide, and insulin in treating gestational diabetes mellitus: A meta-analysis. J Diabetes Res. 2019;2019:9804708. DOI: https://doi.org/10.1155/2019/9804708

Zhen XM, Li X, Chen C. Metformin versus insulin for gestational diabetes: the reporting of ethnicity and a meta-analysis combining English and Chinese literatures. Obesity Medicine. 2018;11:48-58. DOI: https://doi.org/10.1016/j.obmed.2018.08.001

McIver LA, Preuss CV, Tripp J. Acarbose. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026.

Manda RA, Verma V, Biswas K. An open randomized study to compare effect of metformin versus acarbose monotherapy on glycemiccontrol and lipid profile in newly diagnosed type 2 diabetes mellitus patients. Int J Res Med Sci. 2021;9(3):755-60. DOI: https://doi.org/10.18203/2320-6012.ijrms20210873

Cochrane. Review Manager (RevMan) [Computer program]. Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2020. Available at: https://www.cochrane.org/authors/ handbooks-and-manuals/style-manual/references/ reference-types/software. Accessed on 14 March 2026.

Jayasingh S Sr, Nanda S, Misra S, Baliarsinha A, Das S, Patil A. Comparison of fetomaternal outcomes in patients with gestational diabetes mellitus treated with insulin versus acarbose: Results of a prospective, open label, controlled study. Cureus. 2020;12(12):e12283. DOI: https://doi.org/10.7759/cureus.12283

Bertini AM, Silva JC, Taborda W, Becker F, Lemos Bebber FR, Zucco Viesi JM, et al. Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med. 2005;33(6):519-23. DOI: https://doi.org/10.1515/JPM.2005.092

Villarreal-Rodriguez JA, Mancillas Adame LG, Maldonado-Sanchez J, Guzmán-López A, Treviño-Montemayor OR, Gonzalez-Gonzalez JG, et al. A randomized controlled trial comparing acarbose vs. insulin therapy for gestational diabetes in individuals with inadequate glycemic control by diet alone. Clin Exp Obstet Gynecol. 2020;47(4):552-5. DOI: https://doi.org/10.31083/j.ceog.2020.04.5026

Sharon M, Bashutheen NS. Comparative study between acarbose and insulin in the treatment of GDM. Annal Internasion Med Dent Res. 2018;4(2):16-20. DOI: https://doi.org/10.21276/aimdr.2018.4.2.OG5

Margarita de Veciana, Trail PA, Evans AT, Dulaney K. A comparison of oral acarbose and insulin in women with gestational diabetes mellitus. Obstet Gynecol. 2002;99:5S. DOI: https://doi.org/10.1097/00006250-200204001-00009

Uuh Narvaez JJ, Segura Campos MR. Combination therapy of bioactive compounds with acarbose: A proposal to control hyperglycemia in type 2 diabetes. J Food Biochem. 2022;46(10):e14268. DOI: https://doi.org/10.1111/jfbc.14268

DiNicolantonio JJ, Bhutani J, O'Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open heart. 2015;2(1):327. DOI: https://doi.org/10.1136/openhrt-2015-000327

He K, Shi JC, Mao XM. Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clin Risk Manag. 2014;10:505-11. DOI: https://doi.org/10.2147/TCRM.S50362

Singh AN, Patel MI, Shah KR, Unadkat V. A comprehensive review on acarbose in glycaemia control: current insights and future prospects. Int J Basic Clin Pharmacol. 2025;14(3):428-36. DOI: https://doi.org/10.18203/2319-2003.ijbcp20251072

Wettergreen SA, Sheth S, Malveaux J. Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus. Pharm Pract (Granada). 2016;14(4):832. DOI: https://doi.org/10.18549/PharmPract.2016.04.832

Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: A placebo-controlled dose-comparison study. Diabetes Care. 1995;18(6):817-24. DOI: https://doi.org/10.2337/diacare.18.6.817

Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(2):CD003639. DOI: https://doi.org/10.1002/14651858.CD003639.pub2

Chiasson JL, Josse RG, Gomis R. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA. 2003;290(4):486-94. DOI: https://doi.org/10.1001/jama.290.4.486

Kunarathnam V, Vadakekut ES, Mahdy H. Gestational Diabetes. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2026.

Ferreira NA, Junior LGL, Sato ID, Rodrigues JAM, Leite MS. Gestational diabetes mellitus and neonatal complications: Macrosomia, neonatal hypoglycemia and shoulder dystocia. Int J Sci Res Arc. 2025;17(02):567-9. DOI: https://doi.org/10.30574/ijsra.2025.17.2.3063

Chen YS, Ho CH, Lin SJ, Tsai WH. Identifying additional risk factors for early asymptomatic neonatal hypoglycemia in term and late preterm babies. Pediatr Neonatol. 2022;63(6):625-32. DOI: https://doi.org/10.1016/j.pedneo.2022.04.011

Cao Y, Yang Y, Liu L, Ma J. Analysis of risk factors of neonatal hypoglycemia and its correlation with blood glucose control of gestational diabetes mellitus: A retrospective study. Medicine (Baltimore). 2023;102(35):e34619. DOI: https://doi.org/10.1097/MD.0000000000034619

Sousa KS, Leite HV, Corrêa MD, Sousa MS, Queiroz ALR. Prevalence of macrosomic newborn and maternal and neonatal complications in a high-risk maternity. Rev Bras Ginecol Obstet. 2024;46:e-rbgo48. DOI: https://doi.org/10.61622/rbgo/2024rbgo48

Rubarth LB. Infants of diabetic mothers. Neonat Network. 2013;32(6):416-8. DOI: https://doi.org/10.1891/0730-0832.32.6.416